Please assess the completion status of the following clinical trial:

Trial Title: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
The inclusion criteria included, but were not limited to, the following:~1. Chronic Atopic Dermatitis that had been present for at least 3 years~2. History of inadequate response to out-patient treatment with topical medications, or for whom topical treatments were otherwise inadvisable (e.g, because of important side effects or safety risks)~3. Willing and able to comply with all clinic visits and study-related procedures~The exclusion criteria included, but were not limited to, the following:~1. Prior treatment with dupilumab (REGN668/SAR231893)~2. Presence of certain laboratory abnormalities at the screening visit~3. Treatment with an investigational drug within 8 weeks of baseline visit~4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit~5. Certain other treatments and medical procedures undertaken within a particular time frame prior to the baseline visit~6. Known history of human immunodeficiency virus (HIV) infection~7. History of malignancy within 5 years before the baseline visit (with certain exceptions)~8. Planned surgical procedure during the length of the study~9. High risk of parasite infection~10. Any other medical or psychological condition that in the opinion of the investigator or the sponsor's medical monitor, would place the participants at risk, interfere with participation in the study or interfere with interpretation of study results~11. Pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo qw (Type: EXPERIMENTAL): Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.
- Dupilumab 300 mg qw (Type: EXPERIMENTAL): Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
- Dupilumab 300 mg q2w (Type: EXPERIMENTAL): Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.
- Dupilumab 200 mg q2w (Type: EXPERIMENTAL): Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.
- Dupilumab 300 mg q4w (Type: EXPERIMENTAL): Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
- Dupilumab 100 mg q4w (Type: EXPERIMENTAL): Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete